Crossmark

The antifungal pipeline: a reality check

Crossref DOI link: https://doi.org/10.1038/nrd.2017.46

Published Online: 2017-05-12

Published Print: 2017-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Perfect, John R.
License Information

Text and Data Mining valid from 2017-05-12
More Information

Article History

First Online: 12 May 2017

Competing interests

: The author declares research grants, consulting arrangements, honorariums and advisory committees from the following companies: Merck & Co., Astellas, Pfizer Inc, F2G, Vical, Arno Therapeutics, Cidara, Scynexis, Viamet, Matinas BioPharma, Amplyx Pharmaceuticals and Teva Pharmaceutical Industries.